SM
SMTI
Sanara MedTech Inc.
$20.81
-3.21%
$190.7M
No data for this timeframe.
Vol
Market Cap$190.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders30 funds
Inst. Value$16.2M
Inst. Activity5 buys / 3 sells
SEC Reports5
Press Releases1
Exchange Nasdaq·Sector Orthopedic, Prosthetic & Surgical Appliances & Supplies·Inc. TX·CIK 0000714256·Prev Close $21.50
Recent Activity
Jun 4, 2026
SEC
Sanara MedTech terminated its Transaction Advisory Services Agreement with The Catalyst Group, effective June 2, 2026, i
8-K — Impact 3/10
Jun 4, 2026
Insider
Major Eric D was granted 4,846 shares
Director
Jun 4, 2026
Insider
TANZBERGER ERIC D was granted 5,308 shares
Director
Jun 4, 2026
Insider
Nixon Ronald T was granted 4,154 shares
Director
May 12, 2026
earnings_calendar
SMTI Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
SEC
Sanara MedTech reported Q1 2026 revenue of $27.8M (+19% YoY) and GAAP net income from continuing operations of $0.4M ($0
8-K — Impact 7/10
Apr 17, 2026
SEC
Sanara MedTech Inc. filed a supplemental proxy statement outlining board leadership changes effective upon shareholder a
DEFA14A — Impact 3/10
Inst.
MARSHALL WACE, LLP — ADD
76,282 shares ($1.3M)
Price Targets
$34.00
+63.4% upside
Strong Buy
Current $20.81
Low $32.00
Median $34.00
High $36.00
2 analysts
$32.00
$36.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 15, 2026 | Lake Street | INITIATE | Buy |
| Jan 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.07 | $-0.07 — $-0.07 | 1 | |
| Next Q | $0.02 | $0.02 — $0.02 | 1 | |
| Current FY | $0.18 | $0.18 — $0.18 | 1 | |
| Next FY | $0.54 | $0.54 — $0.54 | 200% YoY | 1 |
Latest Reports
NEUTRAL
8-K
3/10
Sanara MedTech terminated its Transaction Advisory Services Agreement with The Catalyst Group, effective June 2, 2026, i
Jun 4, 2026
BULLISH
8-K
7/10
Sanara MedTech reported Q1 2026 revenue of $27.8M (+19% YoY) and GAAP net income from continuing operations of $0.4M ($0
May 11, 2026
NEUTRAL
Press
3/10
Sanara MedTech Inc. announced it will report its Q4 and full-year 2025 financial results on March 24, 2026, followed by
Mar 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $3.9M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.6M | — |
| ROYAL BANK OF CANADA | $2.3M | ADD |
| MARSHALL WACE, LLP | $1.3M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $1.1M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Major Eric | A | $0.00 |
| Jun 4, 2026 | TANZBERGER ERIC | A | $0.00 |
| Jun 4, 2026 | Nixon Ronald | A | $0.00 |
| Jun 4, 2026 | DeSutter Robert | A | $0.00 |
| Jun 4, 2026 | Mack Roszell | A | $0.00 |
30 institutional holders with $16.2M total value (951,456 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, ROYAL. Net buying activity: 5 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 228,767 | $3.9M | 24.3% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 151,367 | $2.6M | 16.1% | — |
| 3 | ROYAL BANK OF CANADA | 131,389 | $2.3M | 14.0% | ADD +70.9% |
| 4 | MARSHALL WACE, LLP | 76,282 | $1.3M | 8.1% | ADD +56.9% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 64,680 | $1.1M | 6.9% | ADD +72.0% |
| 6 | STATE STREET CORP | 62,689 | $1.1M | 6.7% | — |
| 7 | CITADEL ADVISORS LLC | 31,113 | $534.5K | 3.3% | — |
| 8 | VANGUARD FIDUCIARY TRUST CO | 25,375 | $435.9K | 2.7% | — |
| 9 | GOLDMAN SACHS GROUP INC | 21,585 | $370.8K | 2.3% | — |
| 10 | Baird Financial Group, Inc. | 21,075 | $362.1K | 2.2% | NEAR_EXIT -97.2% |
| 11 | MORGAN STANLEY | 19,640 | $337.4K | 2.1% | TRIM -30.4% |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 18,130 | $311.5K | 1.9% | — |
| 13 | HSBC HOLDINGS PLC | 17,283 | $301.1K | 1.9% | — |
| 14 | D. E. Shaw & Co., Inc. | 16,323 | $280.4K | 1.7% | — |
| 15 | Nuveen, LLC | 15,207 | $261.3K | 1.6% | — |
| 16 | Rockefeller Capital Management L.P. | 14,393 | $247.3K | 1.5% | — |
| 17 | Point72 Asset Management, L.P. | 10,335 | $177.6K | 1.1% | — |
| 18 | DEUTSCHE BANK AG\ | 3,985 | $68.5K | 0.4% | — |
| 19 | RHUMBLINE ADVISERS | 2,170 | $37.3K | 0.2% | TRIM -29.4% |
| 20 | BARCLAYS PLC | 2,105 | $36.2K | 0.2% | DOUBLED +100.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MARSHALL WACE, LLP | ADD | 48,611 | 76,282 | +56.9% | $1.3M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 37,602 | 64,680 | +72.0% | $1.1M | 2026-Q1 |
| Baird Financial Group, Inc. | NEAR_EXIT | 760,293 | 21,075 | -97.2% | $362.1K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 28,227 | 19,640 | -30.4% | $337.4K | 2026-Q1 |
| CWM, LLC | DOUBLED | 155 | 1,112 | +617.4% | $19.1K | 2026-Q1 |
| FMR LLC | TRIM | 1,630 | 892 | -45.3% | $15.3K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 5 | 43 | +760.0% | $739.00 | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 8,698 | 10,898 | +25.3% | $188.00 | 2026-Q1 |
| Baird Financial Group, Inc. | NEW | — | 760,293 | — | $17.8M | 2025-Q4 |
| MARSHALL WACE, LLP | TRIM | 66,073 | 48,611 | -26.4% | $1.1M | 2025-Q4 |
| MORGAN STANLEY | ADD | 18,017 | 28,227 | +56.7% | $659.1K | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 24,458 | 13,154 | -46.2% | $307.1K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 1,865 | 3,322 | +78.1% | $77.6K | 2025-Q4 |
| RHUMBLINE ADVISERS | TRIM | 3,127 | 2,208 | -29.4% | $51.6K | 2025-Q4 |
| FMR LLC | DOUBLED | 267 | 1,630 | +510.5% | $38.1K | 2025-Q4 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 6,598 | 8,698 | +31.8% | $204.00 | 2025-Q4 |
| CWM, LLC | ADD | 85 | 155 | +82.4% | $4.00 | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 32,975 | 24,458 | -25.8% | $776.1K | 2025-Q3 |
| UBS Group AG | TRIM | 7,795 | 3,717 | -52.3% | $117.9K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 2,208 | 3,181 | +44.1% | $100.9K | 2025-Q3 |
| FMR LLC | TRIM | 480 | 267 | -44.4% | $8.5K | 2025-Q3 |
| CWM, LLC | DOUBLED | 36 | 85 | +136.1% | $3.00 | 2025-Q3 |
| MARSHALL WACE, LLP | DOUBLED | 29,274 | 71,511 | +144.3% | $2.0M | 2025-Q2 |
| UBS Group AG | ADD | 5,420 | 7,795 | +43.8% | $221.3K | 2025-Q2 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | TRIM | 2,382 | 1,657 | -30.4% | $47.0K | 2025-Q2 |
12 unique insiders with 22 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Major Eric D | Director | AWARD | 4,846 | — | — |
| Jun 4, 2026 | TANZBERGER ERIC D | Director | AWARD | 5,308 | — | — |
| Jun 4, 2026 | Nixon Ronald T | Director | AWARD | 4,154 | — | — |
| Jun 4, 2026 | DeSutter Robert Andrew | Director | AWARD | 5,539 | — | — |
| Jun 4, 2026 | Mack Roszell III | Director | AWARD | 5,308 | — | — |
| Jun 4, 2026 | Ortwein Sara N | Director | AWARD | 4,616 | — | — |
| Jun 4, 2026 | Salamone Ann Beal | Director | AWARD | 4,154 | — | — |
| Jun 4, 2026 | Myers Keith G | Director | AWARD | 4,385 | — | — |
| May 15, 2026 | Yon Seth D | Chief Executive Officer | TAX W/H | 3,852 | $21.06 | $81.1K |
| Apr 15, 2026 | Waldrop Jacob A. | Chief Operating Officer | TAX W/H | 378 | $20.01 | $7.6K |
| Mar 22, 2026 | Mackey Ashley M | Controller | AWARD | 2,804 | — | — |
| Mar 22, 2026 | Yon Seth D | Chief Executive Officer | AWARD | 25,430 | — | — |
| Mar 22, 2026 | Waldrop Jacob A. | Chief Operating Officer | AWARD | 13,956 | — | — |
| Mar 22, 2026 | Taylor Elizabeth B | Chief Financial Officer | AWARD | 12,687 | — | — |
| Mar 22, 2026 | Mackey Ashley M | Controller | AWARD | 2,804 | — | — |
| Mar 7, 2026 | Yon Seth D | Chief Executive Officer | TAX W/H | 596 | $18.87 | $11.2K |
| Mar 1, 2026 | Yon Seth D | Chief Executive Officer | TAX W/H | 414 | $20.44 | $8.5K |
| Mar 1, 2026 | Yon Seth D | Chief Executive Officer | TAX W/H | 491 | $20.44 | $10.0K |
| Feb 25, 2026 | Waldrop Jacob A. | Chief Operating Officer | TAX W/H | 714 | $19.90 | $14.2K |
| Feb 25, 2026 | Yon Seth D | Chief Executive Officer | TAX W/H | 873 | $19.90 | $17.4K |
| Feb 25, 2026 | Mackey Ashley M | Controller | TAX W/H | 149 | $19.90 | $3.0K |
| Feb 25, 2026 | Taylor Elizabeth B | Chief Financial Officer | TAX W/H | 437 | $19.90 | $8.7K |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.8/10.
NEUTRAL
8-K
3/10
Sanara MedTech terminated its Transaction Advisory Services Agreement with The Catalyst Group, effec
Jun 4, 2026
BULLISH
8-K
7/10
Sanara MedTech reported Q1 2026 revenue of $27.8M (+19% YoY) and GAAP net income from continuing ope
May 11, 2026
NEUTRAL
DEFA14A
3/10
Sanara MedTech Inc. filed a supplemental proxy statement outlining board leadership changes effectiv
Apr 17, 2026
NEUTRAL
DEFA14A
3/10
Sanara MedTech Inc. (SMTI) filed a definitive proxy statement (DEFA14A) to solicit votes for the ele
Apr 17, 2026
NEUTRAL
PRESS-RELEASE
3/10
Sanara MedTech announced it will report Q1 2026 financial results on May 12, 2026, ahead of market o
Apr 14, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$34.00 mean target
+63.4% upside
Strong Buy (3.00)
$32.00 Low
$36.00 High
| Metric | Value |
|---|---|
| Current Price | $20.81 |
| Target Low | $32.00 |
| Target Mean | $34.00 |
| Target Median | $34.00 |
| Target High | $36.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.07 | $-0.07 | $-0.07 | — | — | — | $0.0B | 10.9% | 1 |
| Next Q 2026-09-30 |
$0.02 | $0.02 | $0.02 | — | — | — | $0.0B | 14.7% | 1 |
| Current FY 2026-12-31 |
$0.18 | $0.18 | $0.18 | — | — | — | $0.1B | 13.8% | 1 |
| Next FY 2027-12-31 |
$0.54 | $0.54 | $0.54 | 200.0% | — | — | $0.1B | 12.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.070 | |
| 7d ago | $0.010 | -0.080 |
| 30d ago | $0.000 | -0.070 |
| 60d ago | $0.000 | -0.070 |
| 90d ago | $0.000 | -0.070 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 15, 2026 | Lake Street | INITIATE | — | Buy |
| Jan 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings_calendar
SMTI Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
<p align="center"><i>Net Revenue Growth of </i><i>19%</i><i> and Net Profitability from Continuing Operations of </i><i>$0.04</i><i> Per Fully Diluted
Apr 14, 2026
earnings
Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026
<p align="justify">FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- <b>Sanara MedTech Inc.</b> (“Sanara,” the “Company”, “we,” “our” or “us”) (Nas
Mar 24, 2026
earnings_calendar
SMTI Q4 2025 Earnings After Market Close — 2026-03-24
Mar 11, 2026
other
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
<p align="center"><i>Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX</i><sup><i>®</i></sup><i> as
Mar 3, 2026
earnings
Sanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
<p align="justify"><b>FORT WORTH, TX, March 03, 2026 (GLOBE NEWSWIRE) -- </b>Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nas